---All---
  • ---All---
  • Accession
  • Catalog #

LC3 (APG8a) Antibody (P45) Blocking PeptideSynthetic peptide

Country
United States
Australia Austria Belgium Brazil Bulgaria Canada China Croatia Cyprus Czech Republic Denmark Estonia Finland France Germany Greece Hungary Iceland India Indonesia Ireland Israel Italy Japan Korea Latvia Lithuania Luxembourg Macedonia Malaysia Malta Netherlands Norway Pakistan Poland Portugal Romania Serbia Singapore Slovakia Slovenia Spain Sweden Switzerland Taiwan Turkey United Kingdom United States Vietnam Others
Ordering Information
Catalog # Size Availability Price  
BP1801b 0.1 mg 400 ul In Stock $ 45.00 Add to cart
  • Specification
  • Citiations : 0
  • Reviews
  • Protocols
  • Backgrounds

LC3 (APG8a) Antibody (P45) Blocking Peptide - Product info

Primary AccessionQ9H492
Clone Names70226102
Calculated MW14272 Da

LC3 (APG8a) Antibody (P45) Blocking Peptide - Additional info

Gene ID 84557
Target/Specificity
The synthetic peptide sequence used to generate the antibody AP1801b was selected from the region of human LC3 (APG8a) beginning with residue P45. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Format
The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.
Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.
Precautions
This product is for research use only. Not for use in diagnostic or therapeutic procedures.

LC3 (APG8a) Antibody (P45) Blocking Peptide - Protein Information

Name MAP1LC3A
Function
Involved in formation of autophagosomal vacuoles (autophagosomes)
Cellular Location
Cytoplasm, cytoskeleton. Endomembrane system; Lipid-anchor. Cytoplasmic vesicle, autophagosome membrane; Lipid-anchor. Cytoplasmic vesicle, autophagosome. Note=LC3-II binds to the autophagic membranes
Tissue Location
Most abundant in heart, brain, liver, skeletal muscle and testis but absent in thymus and peripheral blood leukocytes

LC3 (APG8a) Antibody (P45) Blocking Peptide - Related products

AM1800a: LC3 Antibody (APG8)

AM1823a: APG8a (MAP1LC3A)-S12 Antibody

AP1800a: LC3 Antibody (APG8A)

AP1801a: LC3 Antibody (APG8A) (N-term)

AP1801b: LC3 Antibody (APG8A) (P45)

AP1801c: LC3 Antibody (APG8A) (I31)

AP1801d: LC3 Antibody (APG8A) (D106)

AP1801e: LC3 Antibody (APG8A) (S12)

AP1801f: LC3 Antibody (APG8A) (S3)

AP1801g: LC3 Antibody (APG8A) (T93/Y99)

AP1801h: LC3 Antibody (APG8A) (T93/Y99)

AP1801i: LC3 Antibody (Isoform B Specific)

AP1805a: Cleaved LC3A Antibody

AP3301a: Phospho-LC3C-S12 Antibody

AP3620a: Phospho-LC3A-T93 Antibody

AP3641a: Phospho-LC3A-S3 Antibody

AP3706a: Phospho-APG8a (MAP1LC3A)-Y99 Antibody

RI13150: MAP1LC3A predesign siRNA

BP1801a: LC3 Antibody (APG8a) (N-term) Blocking Peptide

BP1801b: LC3 (APG8a) Antibody (P45) Blocking Peptide

BP1801c: LC3 Antibody (APG8a) (I31) Blocking Peptide

BP1801d: LC3 Antibody (APG8a) (D106) Blocking Peptide

BP1801e: APG8a (MAP1LC3A) Antibody (S12) Blocking Peptide

BP1801f: APG8a (MAP1LC3A) Antibody (S3) Blocking Peptide

BP1801g: APG8a (MAP1LC3A) Antibody (T93/Y99) Blocking Peptide

BP1801h: APG8a (MAP1LC3A) Antibody (T93/Y99) Blocking Peptide

BP1801i: APG8a (MAP1LC3A) Antibody (Isoform b specific) Blocking Peptide

BP1805a: Cleaved-LC3 Antibody (APG8a) Blocking Peptide

BP3301a: Phospho-LC3 (APG8a) - S12 Antibody Blocking Peptide

BP3620a: Phospho-APG8a (MAP1LC3A)-pT93 Antibody Blocking Peptide

BP3641a: Phospho-APG8a (MAP1LC3A)-pS3 Antibody Blocking Peptide

BP3706a: Phospho-APG8a(MAP1LC3A)-Y99 Antibody Blocking Peptide

AJ1456a: MAPILC3A Antibody

AJ1456b: MAPILC3A Antibody (C-term)

AJ1456c: MAPILC3A Antibody (N-term)

Abgent welcomes feedback from its customers.

If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.

If you have any additional inquiries please email technical services at tech@abgent.com.

Thank you for your support.


Submit

Provided below are standard protocols that you may find useful for product applications.

BACKGROUND

Macroautophagy is the major inducible pathway for the general turnover of cytoplasmic constituents in eukaryotic cells, it is also responsible for the degradation of active cytoplasmic enzymes and organelles during nutrient starvation. Macroautophagy involves the formation of double-membrane bound autophagosomes which enclose the cytoplasmic constituent targeted for degradation in a membrane bound structure, which then fuse with the lysosome (or vacuole) releasing a single-membrane bound autophagic bodies which are then degraded within the lysosome (or vacuole). MAP1A and MAP1B are microtubule-associated proteins which mediate the physical interactions between microtubules and components of the cytoskeleton. These proteins are involved in formation of autophagosomal vacuoles (autophagosomes). MAP1A and MAP1B each consist of a heavy chain subunit and multiple light chain subunits. MAP1LC3a is one of the light chain subunits and can associate with either MAP1A or MAP1B. The precursor molecule is cleaved by APG4B/ATG4B to form the cytosolic form, LC3-I. This is activated by APG7L/ATG7, transferred to ATG3 and conjugated to phospholipid to form the membrane-bound form, LC3-II.

REFERENCES

Tanida, I., et al., J. Biol. Chem. 279(35):36268-36276 (2004).He, H., et al., J. Biol. Chem. 278(31):29278-29287 (2003).Mann, S.S., et al., J. Neurosci. Res. 43(5):535-544 (1996).